Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-Squamous Non Small Cell Lung Cancer × anlotinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 50 Small Cell Lung Carcinoma 21 Lung Neoplasms 10 NSCLC 5 Non-squamous Non-small Cell Lung Cancer 3 Neoplasms 3 Carcinoma 3 Extensive Stage Small Cell Lung Cancer 2 Brain Neoplasms 2 Adenocarcinoma of Lung 2 Squamous Non-small Cell Lung Cancer 1 Small Cell Lung Cancer Limited Stage 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma 1 SCLC 1 Non-squamous Non-small-cell Lung Cancer 1 Non-squamous Cell Non-Small Cell Lung Cancer 1 Non-Squamous Non Small Cell Lung Cancer 1 Non Small Cell Lung Cancer Recurrent 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Locally Advanced Non-small Cell Lung Cancer 1 Limited Stage Small Cell Lung Cancer 1 IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy 1 Extensive Small Cell Lung Cancer 1 Aumolertinib 1 Advanced Non-small Cell Lung Cancer 1

Interventions

anlotinib 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03646968 2023-12-27

SAVE

Hunan Province Tumor Hospital

Phase 2 Unknown

Non-Squamous Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡